Primary cultures of visceral yolk-sac (VYS) endodermal cells were used to assess the effects of teratogenic and nonteratogenic antibodies. When assessed by cytotoxicity assay, teratogenic antibodies appeared to be lethal to the cultured cells at high concentrations (1.25-5 mg of antibodies per ml of culture medium). At a nonlethal dosage, the teratogenic antibodies induced morphological changes, including retraction and rounding up of living cells. The cytotoxic effect as well as the effect on cell morphology appeared to be dose-dependent and specific to VYS endodermal cells. The mechanisms of cell killing were not the same as those attributed to complement-mediated cell lysis. The nonteratogenic antibodies did not have any cytotoxic effect nor did they cause any cell morphological alterations. The results of this investigation, when interpreted by correlating the dose-dependent effects of the teratogenic antibodies on cultured endodermal cells with the in vivo teratogenic effect, suggest that teratogenic antibodies when given at a teratogenic dose cause congenital abnormalities without killing the VYS endodermal cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jez.1402480310 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.
Lancet Haematol
January 2025
University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Background: In CARTITUDE-4, ciltacabtagene autoleucel (cilta-cel) significantly improved progression-free survival (primary endpoint; previously reported) versus standard of care in patients with relapsed, lenalidomide-refractory multiple myeloma. We report here patient-reported outcomes.
Methods: In the ongoing, phase 3, open-label CARTITUDE-4 study, patients were recruited from 81 sites in the USA, Europe, Asia, and Australia, and were randomly assigned 1:1 to cilta-cel (target, 0·75 × 10 CAR-T cells/kg) or standard of care (daratumumab, pomalidomide, and dexamethasone; pomalidomide, bortezomib, and dexamethasone).
Nanobody-based indirect competitive ELISA for the detection of aflatoxin M1 in dairy products.
Sci Rep
January 2025
Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, College of Food Science and Engineering, Inner Mongolia Agricultural University, Hohhot, 010018, China.
Aflatoxin M1 (AFM1) is known to be carcinogenic, mutagenic, and teratogenic and poses a serious threat to food safety and human health, which makes its surveillance critical. In this study, an indirect competitive ELISA (icELISA) based on a nanobody (Nb M4) was developed for the sensitive and rapid detection of AFM1 in dairy products. In our previous work, Nb M4 was screened from a Bactrian-camel-immunized phage-displayed library.
View Article and Find Full Text PDFDevelopment of a visual immunosensing platform based on fluorescent microspheres for the rapid detection of ochratoxins in cereals.
Food Chem
March 2025
International Joint Research Laboratory for Biointerface and Biodetection, and School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, PR China; State Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi, PR China.
Ochratoxins (OTs, including OTA, OTB, and OTC), exhibit nephrotoxicity, carcinogenicity, teratogenicity, and immunotoxicity, contaminating wheat, maize, and rice, so endangering human health. In this study, we designed and screened haptens using computational chemistry to prepare mAb 4G11, which simultaneously recognized OTA, OTB, and OTC with high sensitivity and specificity. We developed a fluorescent microsphere immunochromatographic assay (FMIA), which could detect the total amount of OTs with a visual detection limit of 0.
View Article and Find Full Text PDFAllocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.
Blood Cancer J
November 2024
Hematology Department, CHU Nantes, Nantes, France.
The International Staging System for multiple myeloma recently underwent a second revision (R2-ISS) to include gain/amplification of 1q21 and account for the additive prognostic significance of multiple high-risk features. The phase 3 ICARIA-MM (isatuximab-pomalidomide-dexamethasone vs. pomalidomide-dexamethasone) and IKEMA (isatuximab-carfilzomib-dexamethasone vs.
View Article and Find Full Text PDFIsatuximab-dexamethasone-pomalidomide combination effects on serum M protein and PFS in myeloma: Development of a joint model using phase I/II data.
CPT Pharmacometrics Syst Pharmacol
December 2024
INSERM, IAME, Université Paris Cité, Paris, France.
Article Synopsis
- * Data from 203 patients from phase I/II clinical trials were used, creating both longitudinal and PFS-specific models that were then integrated into a joint model to capture their interactions.
- * The final model indicated that serum M-protein changes correlate with PFS and validated the dosing regimen of Isa in a pivotal phase III study, supporting ongoing research and treatment approaches in multiple myeloma. *
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!